KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

BeOne Medicines (ONC) Short-Term Debt repayments (2020 - 2025)

Historic Short-Term Debt repayments for BeOne Medicines (ONC) over the last 6 years, with Q2 2025 value amounting to $102.9 million.

  • BeOne Medicines' Short-Term Debt repayments fell 3468.73% to $102.9 million in Q2 2025 from the same period last year, while for Sep 2025 it was $822.5 million, marking a year-over-year increase of 16749.1%. This contributed to the annual value of $704.2 million for FY2024, which is 12747.76% up from last year.
  • According to the latest figures from Q2 2025, BeOne Medicines' Short-Term Debt repayments is $102.9 million, which was down 3468.73% from $172.9 million recorded in Q1 2025.
  • BeOne Medicines' Short-Term Debt repayments' 5-year high stood at $546.7 million during Q4 2024, with a 5-year trough of $16.0 million in Q2 2021.
  • Over the past 5 years, BeOne Medicines' median Short-Term Debt repayments value was $93.0 million (recorded in 2023), while the average stood at $130.1 million.
  • Its Short-Term Debt repayments has fluctuated over the past 5 years, first soared by 157575.73% in 2021, then tumbled by 6077.9% in 2023.
  • BeOne Medicines' Short-Term Debt repayments (Quarter) stood at $205.2 million in 2021, then soared by 32.37% to $271.7 million in 2022, then plummeted by 44.78% to $150.0 million in 2023, then soared by 264.48% to $546.7 million in 2024, then plummeted by 81.19% to $102.9 million in 2025.
  • Its Short-Term Debt repayments was $102.9 million in Q2 2025, compared to $172.9 million in Q1 2025 and $546.7 million in Q4 2024.